This pilot investigation aimed to examine the impact of different concentrations of indigo naturalis on the cellular viability of human periodontal ligament fibroblast (hPDLF) cells. For experimental application on cells, indigo naturalis solutions were prepared at seven varying concentrations (0.025, 0.0375, 0.05, 0.075, 0.1, 0.1125 and 0.15 µg/mL) for the purpose of cellular treatment. To evaluate cell viability, cells were seeded in 96-well plates in triplicate for each concentration. Following a 24-hour treatment period with indigo naturalis, cell viability was assessed using the MTT assay. Statistical analysis of the data was performed using SPSS software, with a P-value of less than 0.05 considered statistically significant. The MTT assay revealed no significant difference in the viability of hPDLF cells between the control group and the indigo naturalis-treated groups (P>0.05). While indigo naturalis did not affect cell viability in this study, it provides important insights into the interactions between herbal compounds and hPDLF cells. This study is limited by the use of a single assay and a 24-hour observation period, which may restrict the generalisability of the findings. Further research is needed to explore the molecular mechanisms behind these interactions, investigate potential synergistic effects, and evaluate longer-term impacts on periodontal conditions.
As this study was conducted using cell cultures, approval from an ethics committee was not required.
We would like to thank all the participants. The findings of this study were presented as a poster at the EuroPerio 11 Congress (14-17 May 2025). This work was supported by the Scientific and Technological Research Council of Türkiye (TÜBİTAK) under the 2224-A Program for participation in international scientific events.
| Primary Language | English |
|---|---|
| Subjects | Pharmaceutical Biochemistry, Pharmaceutical Botany |
| Journal Section | Research Article |
| Authors | |
| Submission Date | October 13, 2025 |
| Acceptance Date | February 3, 2026 |
| Publication Date | March 15, 2026 |
| DOI | https://doi.org/10.12991/jrespharm.1802902 |
| IZ | https://izlik.org/JA34UB36GH |
| Published in Issue | Year 2026 Volume: 30 Issue: 2 |